» Articles » PMID: 17018596

ERCC4 Associated with Breast Cancer Risk: a Two-stage Case-control Study Using High-throughput Genotyping

Overview
Journal Cancer Res
Specialty Oncology
Date 2006 Oct 5
PMID 17018596
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The failure of linkage studies to identify further high-penetrance susceptibility genes for breast cancer points to a polygenic model, with more common variants having modest effects on risk, as the most likely candidate. We have carried out a two-stage case-control study in two European populations to identify low-penetrance genes for breast cancer using high-throughput genotyping. Single-nucleotide polymorphisms (SNPs) were selected across preselected cancer-related genes, choosing tagSNPs and functional variants where possible. In stage 1, genotype frequencies for 640 SNPs in 111 genes were compared between 864 breast cancer cases and 845 controls from the Spanish population. In stage 2, candidate SNPs identified in stage 1 (nominal P < 0.01) were tested in a Finnish series of 884 cases and 1,104 controls. Of the 10 candidate SNPs in seven genes identified in stage 1, one (rs744154) on intron 1 of ERCC4, a gene belonging to the nucleotide excision repair pathway, was associated with recessive protection from breast cancer after adjustment for multiple testing in stage 2 (odds ratio, 0.57; Bonferroni-adjusted P = 0.04). After considering potential functional SNPs in the region of high linkage disequilibrium that extends across the entire gene and upstream into the promoter region, we concluded that rs744154 itself could be causal. Although intronic, it is located on the first intron, in a region that is highly conserved across species, and could therefore be functionally important. This study suggests that common intronic variation in ERCC4 is associated with protection from breast cancer.

Citing Articles

Non-coding regions of nuclear-DNA-encoded mitochondrial genes and intergenic sequences are targeted by autoantibodies in breast cancer.

Obaidat D, Giordo R, Kleinbrink E, Banisad E, Grossman L, Arshad R Front Genet. 2023; 13:970619.

PMID: 37082114 PMC: 10111166. DOI: 10.3389/fgene.2022.970619.


Mutation analysis of the ERCC4/FANCQ gene in hereditary breast cancer.

Kohlhase S, Bogdanova N, Schurmann P, Bermisheva M, Khusnutdinova E, Antonenkova N PLoS One. 2014; 9(1):e85334.

PMID: 24465539 PMC: 3897449. DOI: 10.1371/journal.pone.0085334.


Association between single nucleotide polymorphisms in ERCC4 and risk of squamous cell carcinoma of the head and neck.

Yu H, Liu Z, Huang Y, Yin M, Wang L, Wei Q PLoS One. 2012; 7(7):e41853.

PMID: 22848636 PMC: 3407112. DOI: 10.1371/journal.pone.0041853.


Association between XPF polymorphisms and cancer risk: a meta-analysis.

Shi T, He J, Qiu L, Zhu M, Wang M, Zhou X PLoS One. 2012; 7(7):e38606.

PMID: 22768293 PMC: 3388076. DOI: 10.1371/journal.pone.0038606.


MAP3K7 and GSTZ1 are associated with human longevity: a two-stage case-control study using a multilocus genotyping.

Di Cianni F, Campa D, Tallaro F, Rizzato C, De Rango F, Barale R Age (Dordr). 2012; 35(4):1357-66.

PMID: 22576335 PMC: 3705096. DOI: 10.1007/s11357-012-9416-8.